2025
Applying single cell profiling to assess drug anti fibrotic properties in the human precision cut lung slice model of fibrosis
Justet A, Mitash N, Pineda R, Adams T, Balayev A, Abu Hussein N, Ishizuka M, Kim H, Khoury J, Cala-García J, Ahangari F, Yan X, Kaminski N, Königshoff M. Applying single cell profiling to assess drug anti fibrotic properties in the human precision cut lung slice model of fibrosis. Revue Des Maladies Respiratoires 2025, 42: 223. DOI: 10.1016/j.rmr.2025.02.083.Peer-Reviewed Original ResearchAbnormal cell populationsAlveolar epithelial cellsTreated with drugsAnti-fibrotic propertiesSingle cell platformsSingle nuclear RNA sequencingLigand-receptor analysisPreclinical evidencePulmonary fibrosisBasaloid cellsFibrotic propertiesReceptor analysisFibrotic pathwaysCell signaturesClinical trialsProfibrotic genesAnti-fibroticFDA-approved drugsGene signatureAnimal modelsEpithelial cellsGene expression changesDay 5Drug efficacyCell profiles
2024
Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression
Lee Y, Chowdhury T, Kim S, Yu H, Kim K, Kang H, Kim M, Kim J, Kim Y, Ji S, Hwang K, Han J, Hwang J, Yoo S, Lee K, Choe G, Won J, Park S, Lee Y, Shin J, Park C, Kim C, Kim J. Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression. Experimental & Molecular Medicine 2024, 56: 975-986. PMID: 38609519, PMCID: PMC11059271, DOI: 10.1038/s12276-024-01204-3.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingNeuronal development pathwaysDrivers of tumorigenesisGlial cell differentiationMethylation sequencingGenomic eventsPI3K-Akt activationDownstream eventsGene markersMultiomics approachCell differentiationRadial glial cellsHypomethylationOverexpressionSequenceTumorigenesisFGFR3Cell signaturesGlial cellsPotential roleCellsTumor cellsCentral nervous systemMultiomicsOntogeny
2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply